Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX-8025 in Homozygous Familial Hypercholesterolemia
NCT02472535Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of seladelpar in homozygous familial hypercholesterolemia (HoFH), sponsored by Gilead Sciences. Started Apr 2015; status: completed.
02
Drugs
seladelpar
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02472535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472535.